ReviewJournal of neural transmission (Vienna, Austria : 1996)2015
Clinical applications of CYP genotyping in psychiatry.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Leukocytosis Associated with Clozapine Treatment: A Case Series and Systematic Review of the Literature.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Translational psychiatry · 2021Pooled it
- The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.Journal of clinical psychopharmacology · 2018Trial
- Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.European journal of clinical pharmacology · 2016Trial
- Beyond MIDAS: AnACS omega · 2026Article
- Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Drug-Drug Interactions and Outcome.Oncology research · 2026Article
- Moving toward precision and personalized treatment strategies in psychiatry.The international journal of neuropsychopharmacology · 2025Review
- Pharmaco-Multiomics: A New Frontier in Precision Psychiatry.International journal of molecular sciences · 2025Review
- Near, far, wherever you are: phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature.Frontiers in pharmacology · 2025Article
- Investigating Remedial Strategies for Missed or Delayed Dose of Sertraline in Chinese Adolescent Patients with Depressive Disorders via Population Pharmacokinetics Modeling and Simulation Approaches.Drug design, development and therapy · 2025Article
- Phenoconversion andHepatology forum · 2025Review
- Comparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study.Psychiatry investigation · 2024Article
- The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.Pharmacopsychiatry · 2024Article
- Therapeutic Drug Monitoring and Pharmacogenetic Testing as Guides to Psychotropic Drug Dose Adjustment: An Observational Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study.Biomedicines · 2023Article
- Study on the daily dose and serum concentration of clozapine in psychiatric patients and possible influencing factors of serum concentration.BMC psychiatry · 2023Article
- The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.Genes · 2023Review
- Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.European journal of clinical pharmacology · 2023Review
- Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing.Psychiatry investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A critical review of the limited available evidence and the authors' experience and judgment are used to summarize the role of cytochrome P450 (CYP) genetic variants in the pharmacokinetics of and clinical response to psychotropic medications. CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 genetic polymorphisms and their contributions to the metabolism of psychotropic drugs are reviewed. CYP1A2, CYP2B6 and CYP3A4 genotyping have limited current clinical utility. CYP2C9 genotyping has no utility in psychiatry. Psychiatrists should master tricyclic antidepressant (TCA) prescription, and if they use TCAs, they should have expertise in CYP2D6 and CYP2C19 genotyping and in TCA therapeutic drug monitoring (TDM) to safely dose TCAs. Practice guidelines recommend dose changes, TDM or alternate drugs for (1) CYP2C19 ultrarapid metabolizers (UM) taking citalopram or escitalopram; (2) CYP2C19 poor metabolizers (PMs) taking sertraline; (3) CYP2D6 PMs taking venlafaxine, aripiprazole, haloperidol, risperidone or zuclopenthixol; and (4) CYP2D6 UMs taking venlafaxine, aripiprazole, haloperidol, risperidone, zuclopenthixol or atomoxetine. According to the prescribing information, CYP2D6 PMs should receive 75 % of the average long-acting aripiprazole dose and pimozide doses >4 mg/day should not be prescribed without CYP2D6 genotyping. In a situation of limited evidence, there is need to use the available pharmacological mechanistic information for better personalizing treatment in psychiatry. This is best done by combining CYP genotyping with TDM. Clozapine and risperidone concentration-to-dose ratios are provided as two examples of this approach of how to integrate CYP genotyping and TDM in psychiatry. New studies are needed to verify that CYP2C19 PM genotyping may have potential to identify clozapine PMs and explain the lower clozapine metabolic capacity in East Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.